Innoviva, Inc. (INVA) stock
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)
Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –
Innoviva total assets
Total assets on the balance sheet at the end of each period.
Innoviva's total assets was $1.54B at Sep 30, 2026. For fiscal 2025 it was $1.64B, up 25.7% from the year before. Over ten years it grew 14.9% a year on average. The highest annual figure on record is $1.64B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.64B | +25.7% |
| FY2024 | Dec 31, 2024 | $1.30B | +4.6% |
| FY2023 | Dec 31, 2023 | $1.24B | +1.0% |
| FY2022 | Dec 31, 2022 | $1.23B | +32.9% |
| FY2021 | Dec 31, 2021 | $926.40M | -7.3% |
| FY2020 | Dec 31, 2020 | $999.57M | +37.9% |
| FY2019 | Dec 31, 2019 | $724.83M | +32.2% |
| FY2018 | Dec 31, 2018 | $548.19M | +49.2% |
| FY2017 | Dec 31, 2017 | $367.34M | -3.1% |
| FY2016 | Dec 31, 2016 | $379.00M | -7.3% |
| FY2015 | Dec 31, 2015 | $408.93M | -21.6% |
| FY2014 | Dec 31, 2014 | $521.65M | -23.4% |
| FY2013 | Dec 31, 2013 | $681.26M | +84.8% |
| FY2012 | Dec 31, 2012 | $368.58M | +42.4% |
| FY2011 | Dec 31, 2011 | $258.78M | -21.9% |
| FY2010 | Dec 31, 2010 | $331.20M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.54B | +7.6% |
| Q2 FY2026 | Jun 30, 2026 | $1.70B | +27.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.84B | +46.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.64B | +25.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.43B | +16.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.33B | +8.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.25B | -1.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.30B | +4.6% |
| Q3 FY2024 | Sep 30, 2024 | $1.23B | +3.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.22B | +9.5% |
| Q1 FY2024 | Mar 31, 2024 | $1.27B | +12.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.24B | +1.0% |
| Q3 FY2023 | Sep 30, 2023 | $1.19B | -10.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.12B | -1.7% |
| Q1 FY2023 | Mar 31, 2023 | $1.13B | +2.0% |
| Q4 FY2022 | Dec 31, 2022 | $1.23B | +32.9% |
| Q3 FY2022 | Sep 30, 2022 | $1.33B | +49.6% |
| Q2 FY2022 | Jun 30, 2022 | $1.14B | +44.2% |
| Q1 FY2022 | Mar 31, 2022 | $1.11B | +1.8% |
| Q4 FY2021 | Dec 31, 2021 | $926.40M | -7.3% |
| Q3 FY2021 | Sep 30, 2021 | $887.24M | -3.8% |
| Q2 FY2021 | Jun 30, 2021 | $789.15M | -10.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.09B | +38.1% |
| Q4 FY2020 | Dec 31, 2020 | $999.57M | +37.9% |
| Q3 FY2020 | Sep 30, 2020 | $922.26M | +36.4% |
| Q2 FY2020 | Jun 30, 2020 | $879.62M | +36.9% |
| Q1 FY2020 | Mar 31, 2020 | $788.01M | +33.5% |
| Q4 FY2019 | Dec 31, 2019 | $724.83M | +32.2% |
| Q3 FY2019 | Sep 30, 2019 | $675.95M | +143.4% |
| Q2 FY2019 | Jun 30, 2019 | $642.31M | +89.6% |
| Q1 FY2019 | Mar 31, 2019 | $590.11M | +113.2% |
| Q4 FY2018 | Dec 31, 2018 | $548.19M | +49.2% |
| Q3 FY2018 | Sep 30, 2018 | $277.69M | -29.0% |
| Q2 FY2018 | Jun 30, 2018 | $338.69M | -9.0% |
| Q1 FY2018 | Mar 31, 2018 | $276.75M | -29.4% |
| Q4 FY2017 | Dec 31, 2017 | $367.34M | -3.1% |
| Q3 FY2017 | Sep 30, 2017 | $390.97M | – |
| Q2 FY2017 | Jun 30, 2017 | $372.02M | – |
| Q1 FY2017 | Mar 31, 2017 | $391.87M | – |
| Q4 FY2016 | Dec 31, 2016 | $379.00M | – |
See a number that looks wrong?